Phaseline

Targets › FUS

FUS (RNA-binding protein FUS): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Mar 2028.

DNA/RNA-binding protein that plays a role in various cellular processes such as transcription regulation, RNA splicing, RNA transport, DNA repair and damage response. Binds to ssRNA containing the consensus sequence 5'-AGGUAA-3'. Binds to nascent pre-mRNAs and acts as a molecular mediator between RNA polymerase II and U1 small nuclear ribonucleoprotein thereby coupling transcription and splicing. (UniProt, P35637)

Open in Phaseline: the race on FUS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ionis PharmaceuticalsION363
Antisense oligonucleotide targeting FUS mRNA
FUSPhase 3Amyotrophic Lateral SclerosisMar 2028

Conditions

Amyotrophic Lateral Sclerosis (1)

Modalities

small molecule (1)

Companies

Ionis Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.